Novavax to Participate in 2024 Jefferies Global Healthcare Conference

Rhea-AI Summary

Novavax (Nasdaq: NVAX) announced its participation in the 2024 Jefferies Global Healthcare Conference.

The event includes a Fireside Chat on June 6, 2024, from 12:30 – 12:55 p.m. ET in New York, NY, moderated by Roger Song, MD, CFA, an Equity Research Analyst in Biotechnology. John C. Jacobs, Novavax's President and CEO, will represent the company.

Additionally, Novavax will hold investor meetings on the same day. A replay of the fireside session will be available on the company's website for 30 days post-conference.

Positive

• Novavax's participation in a high-profile conference increases visibility and investor engagement.
• Representation by CEO John C. Jacobs indicates strong leadership presence.
• Availability of session replay enhances accessibility for interested shareholders.

Negative

• No immediate financial data or clinical results were announced, providing actionable insights for investors.
• Potential investor concerns if no new information is divulged during the conference.

GAITHERSBURG, Md., May 30, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced it will participate in the 2024 Jefferies Global Healthcare Conference.

Conference Details:
Fireside Chat
Date:		Thursday, June 6, 2024
Time:		12:30 – 12:55 p.m. Eastern Time (ET)
Location:		New York, NY
Moderator:		Roger Song, MD, CFA, Equity Research Analyst – Biotechnology
Novavax participant:		John C. Jacobs, President and Chief Executive Officer
Conference
Event:		Investor Meetings
Date:		Thursday, June 6, 2024

Recordings
A replay of the recorded fireside session will be available through the Events & Presentations page of the Company's website at ir.novavax.com for 30 days from the date of the conference.

About Novavax
Novavax, Inc. (Nasdaq: NVAX) promotes improved health by discovering, developing and commercializing innovative vaccines to help protect against serious infectious diseases. Novavax, a global company based in Gaithersburg, Md., U.S., offers a differentiated vaccine platform that combines a recombinant protein approach, innovative nanoparticle technology and Novavax's patented Matrix-M adjuvant to enhance the immune response. The Company's portfolio includes its COVID-19 vaccine and its pipeline includes COVID-19-Influenza Combination and stand-alone influenza vaccine candidates. In addition, Novavax's adjuvant is included in the University of Oxford and Serum Institute of India's R21/Matrix-M malaria vaccine. Please visit novavax.com and LinkedIn for more information.

Contacts:
Investors
Erika Schultz
240-268-2022
ir@novavax.com

Media
Giovanna Chandler
240-720-7804
media@novavax.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/novavax-to-participate-in-2024-jefferies-global-healthcare-conference-302158433.html

SOURCE Novavax, Inc.

FAQ

When is Novavax participating in the 2024 Jefferies Global Healthcare Conference?

Novavax will participate on June 6, 2024.

What time is the Novavax Fireside Chat at the Jefferies Conference?

The Fireside Chat is scheduled from 12:30 – 12:55 p.m. ET.

Who will represent Novavax at the 2024 Jefferies Global Healthcare Conference?

John C. Jacobs, President and CEO of Novavax, will represent the company.

Where can I watch a replay of the Novavax session at the Jefferies Conference?

A replay will be available on the company's website at ir.novavax.com for 30 days after the conference.

What is the stock symbol for Novavax?

Novavax is traded under the stock symbol 'NVAX'.